SMMT - AstraZeneca dominates Merck's Keytruda beaten as ASCO 2024 concludes
2024-06-08 10:19:36 ET
More on AstraZeneca, Bristol-Myers, etc.
- Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Transcript)
- Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84%
- Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss
- Bristol Myers Squibb inks clinical trial pact with I-Mab
- Bristol's Opdivo + Yervoy bests Lenvima, Nexavar in first-line liver cancer